Sign inJoin waitlistJoin the waitlist

John Giudicessi

Assistant Professor of Medicine · Mayo Clinic College of Medicine and Science

Credentials: · · · · ·

History

Mayo Clinic College of Medicine and Science
Present

Cardiovascular Disease
Mayo Clinic College of Medicine and Science
2014–2021
Internal Medicine
Mayo Clinic College of Medicine and Science
2014–2017
Mayo Clinic Alix School of Medicine
2010–2014

Research

European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement…
Europace · 2022 · 302 citations
Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19)
Mayo Clinic Proceedings · 2020 · First of 4 authors · 286 citations
Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization
Systematic review or meta-analysis · Nature Genetics · 2014 · 249 citations

Michael Ackerman
162 papers
Konstantinos Siontis
29 papers · 10 as a fellow
Matteo Castrichini
25 papers · 22 as a fellow
Ramin Garmany
25 papers
SB
Sahej Bains
22 papers · 6 as a resident
Jeffrey Geske
21 papers
Steve Ommen
21 papers
Samuel Asirvatham
14 papers
Ammar Killu
12 papers · 10 as a fellow
Ciorsti MacIntyre
12 papers · 3 as a fellow
Drew Rosenbaum
12 papers · 7 as a fellow
John Bois
11 papers

Grants

The Role of The Transient Outward Current In Genetically Elusive Sudden Death
National Heart, Lung, and Blood Institute · F30
Contact PI · $134K · Mayo Clinic Rochester
2011–2015

Clinical trials

A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
Site PI · Recruiting · Phase 1
Rocket Pharmaceuticals Inc.
2026–2029
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Site PI · Recruiting · Phase 1
Solid Biosciences Inc.
2026–2031
International CRDS Registry
Site PI · Recruiting
Population Health Research Institute
2024–2050
Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC
Site PI · Recruiting · Phase 1
Tenaya Therapeutics
2024–2029